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BACKGROUND: The FIRE AND ICE trial assessed efficacy and safety of 
pulmonary vein (PV) isolation using cryoballoon versus radiofrequency 
current (RFC) ablation in patients with drug refractory, symptomatic, 
paroxysmal atrial fibrillation (AF). The purpose of the current study was to 
assess index lesion durability as well as reablation strategy and outcomes 
in trial patients undergoing a reablation procedure.
METHODS: Patients with reablation procedures during FIRE AND ICE 
were retrospectively consented and enrolled at 13 trial centers. The first 
reablation for each patient was included in the analysis. Documented 
arrhythmias before reablation, number and location of reconnected PVs, 
lesions created during reablations, procedural characteristics, and acute as 
well as long-term outcomes were assessed.
RESULTS: Eighty-nine (36 cryoballoon and 53 RFC) patients were 
included in this study. Paroxysmal atrial fibrillation was the predominant 
recurrent arrhythmia (69%) before reablation. Reablations occurred at 
a median of 173 and 182 days (P=0.54) in the cryoballoon and RFC 
cohorts, respectively. The number of reconnected PVs was significantly 
higher in the RFC than the cryoballoon group (2.1±1.4 versus 1.4±1.1; 
P=0.010), which was driven by significantly more reconnected left 
superior PVs and markedly more reconnected right superior PVs. The 
number of (predominantly RFC) lesions applied during reablation was 
significantly greater in patients originally treated with RFC (3.3±1.3 versus 
2.5±1.5; P=0.015) with no difference in overall acute success (P=0.70). 
After reablation, no differences in procedure-related rehospitalization or 
antiarrhythmic drug utilization were observed between cohorts.
CONCLUSIONS: At reablation, patients originally treated with the 
cryoballoon had significantly fewer reconnected PVs, which may reflect RFC 
catheter instability in certain left atrial regions, and thus required fewer lesions 
for reablation success. Repeat ablations were predominantly performed with 
RFC and resulted in similar acute success, duration of hospitalization, and 
antiarrhythmic drug prescription between the study cohorts.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT03314753.
VISUAL OVERVIEW:  A visual overview is available for this article.
*A list of all FIRE AND ICE study 
participants is given in the Appendix.
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Durable pulmonary vein isolation (PVI) is funda-mental to freedom from atrial arrhythmia recur-rence and is the primary goal when treating pa-
tients with paroxysmal atrial fibrillation (AF) via catheter 
ablation.1,2 PVI is either achieved by heating of cardiac 
tissue with a focal radiofrequency current (RFC) cath-
eter or by freezing the tissue with a cryoballoon cath-
eter.1–3 The FIRE AND ICE trial is the largest, random-
ized, multinational comparative study of efficacy and 
safety of these 2 ablation modalities for the treatment 
of paroxysmal AF by way of PVI.3 The trial established 
that cryoballoon ablation was noninferior to RFC abla-
tion with respect to the primary efficacy and safety end 
points.3 Yet, patients treated with the cryoballoon had 
significantly fewer repeat ablations, direct-current car-
dioversions, all-cause rehospitalizations, and cardiovas-
cular rehospitalizations during follow-up.4 Differences 
in lesion durability between the treatment cohorts are 
unknown.
Prospective evaluations of lesion durability are lim-
ited by the invasive, therapeutically unnecessary nature 
of a remapping procedure; therefore, insight into lesion 
durability has been gleaned during reablation proce-
dures. While comparative evaluations of PVI durability 
have been conducted,5–8 to our knowledge, the pres-
ent analysis is the largest multicenter examination of 
reablation data from an originally randomized trial that 
compared RFC and cryoballoon catheter ablation. The 
purpose of the present analysis was to evaluate index 
PVI lesion durability among FIRE AND ICE trial patients 
who underwent a reablation procedure. Because there 
was a lower rate of reablation observed in the cryobal-
loon cohort, we hypothesized that index cryoballoon 
PVI was more durable than index RFC PVI in patients 
who ultimately underwent a reablation in this trial.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Study Design
The FIRE AND ICE Redo study was an observational, ret-
rospective evaluation of patients who underwent a repeat 
ablation during the FIRE AND ICE trial to compare arrhythmia 
recurrence, number and anatomic pattern of reconnected 
PVs, and index PVI lesion durability in patients originally 
randomized to cryoballoon or RFC ablation. Of the 16 sites 
that participated in FIRE AND ICE, 13 sites in Europe (listed 
below) participated in this trial. The trial was approved by 
each site’s ethics committee/institutional review board, reg-
istered, and conducted in accordance with the Declaration 
of Helsinki. Data to fulfill the predefined objectives about 
the index procedure, patient characteristics following the 
index, and the repeat ablation procedures were collected. 
An independent end point review committee (blinded to 
randomization) reviewed and adjudicated all repeat abla-
tion study data.
Patient Cohort
Patients enrolled in the original trial were between the ages 
of 18 and 75 years old and had drug refractory, symptom-
atic, paroxysmal AF.3 On average, these patients were fol-
lowed 1.5±0.8 years post the index ablation and underwent 
a repeat procedure after evidence of arrhythmia recurrence 
was documented and at the discretion of the patient and 
operating physician. A total of 110 patients from the FIRE 
AND ICE modified intention to treat cohort collectively 
underwent a total of 119 repeat ablations during follow-
up. Of the 119 reablations, 49 were performed in 44 sub-
jects who had undergone an index cryoballoon ablation 
procedure, and 70 were performed in 66 subjects who 
had undergone an index RFC ablation procedure (Table 1).4 
Patients with a documented repeat ablation at any time 
during the original trial (regardless of the 90-day blank-
ing period) were included in this evaluation after providing 
written informed consent; no new subjects were enrolled 
into this current evaluation. In patients who underwent 
multiple reablations, only the first reablation was included 
in this analysis. Patients who underwent a repeat procedure 
following an index cryoballoon ablation were denoted as 
WHAT IS KNOWN?
• Durable pulmonary vein isolation is fundamental 
to freedom from atrial arrhythmia recurrence and 
is the primary goal when treating patients with 
paroxysmal atrial fibrillation via catheter ablation.
• In the FIRE AND ICE trial, a significantly higher rate 
of reablation was observed in patients treated with 
radiofrequency ablation than in patients treated 
with cryoballoon ablation (17.6% versus 11.8%, 
respectively, P=0.03).
WHAT THE STUDY ADDS?
• In patients who underwent a repeat ablation in 
FIRE AND ICE, significantly fewer pulmonary veins 
were reconnected in patients treated with the 
cryoballoon than in patients treated with radiofre-
quency current (1.4±1.1 versus 2.1±1.4; P=0.010). 
Accordingly, fewer lesion sets were applied dur-
ing the reablation procedure in patients initially 
treated with the cryoballoon (2.5±1.5 versus 
3.3±1.3; P=0.015), suggesting that cryoballoon 
lesions were more durable than radiofrequency 
lesions in this trial.
• The anatomic distribution of reconnected pulmo-
nary veins differed between patients treated with 
cryoballoon versus radiofrequency ablation dur-
ing the index procedure, which may suggest that 
the cryoballoon more aptly achieves the catheter 
stability required to achieve durable PVI in ana-
tomically challenging areas such as the myocardial 
ridge separating the left-sided pulmonary veins 
from the left atrial appendage.
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cryoballoon-Redo, and patients who underwent a repeat 
procedure following an index RFC ablation were denoted 
as RFC-Redo.
Patient Assessment Before Repeat 
Ablation
Baseline patient characteristics collected at the time of 
enrollment in FIRE AND ICE were compared between reab-
lation cohorts. Data from the index ablation as well as the 
type of arrhythmia recurrence before the repeat ablation 
were collected. Documented arrhythmia recurrence before 
the reablation was categorized as paroxysmal or persistent 
AF, atrial tachycardia, and typical/atypical atrial flutter.
Repeat ablation procedures were performed at the same 
hospital center as the index ablation. Both PV and non-PV 
locations were evaluated for arrhythmic potential at the time 
of the reablation procedure. PVI was confirmed via bidirec-
tional entrance and exit block. Information about the number 
and location of gaps in the PV lesions captured via a focal 
catheter or 3-dimensional electroanatomical mapping were 
documented as available. Spot gaps were predefined as 1 mm 
in size requiring a single application without catheter move-
ment to reisolate the PV or cause a change in the PV activation 
sequence. A linear gap was defined as a gap that required 
multiple applications or dragging of the RFC catheter.
Repeat Ablation Protocol
If PV reconnection was observed, PV reisolation was per-
formed and verified by entrance and exit block testing. It 
was recommended that the same energy source to which the 
patient was randomized in FIRE AND ICE for the index abla-
tion be applied during the reablation; however, the ablation 
modality used during repeat ablation was ultimately left to 
the discretion of the operator. Cryoballoon and RFC ablation 
methods have been described in detail.3 Additional ablation 
of substrate or potential focal AF triggers was allowed dur-
ing the procedure at the discretion of the treating physician. 
Lesion sets applied during repeat ablation were classified as 
one of the following: (Re-) PVI, left atrial (LA) trigger, right 
atrial trigger, superior vena cava trigger, inferior vena cava 
trigger, cavotricuspid isthmus block, mitral valve isthmus line, 
left-sided roofline, complex fractionated atrial electrogram 
ablation, posterior wall line, atrioventricular nodal reentry 
tachycardia ablation, or other lesion sets that were not pre-
defined. Acute procedural success was defined as reisolation 
of the PVs by entrance/exit block and the elimination of a trig-
ger or a line of bidirectional conduction block when adjunc-
tive ablations were performed. Reablation total procedure 
time, LA dwell time, and fluoroscopy time were recorded for 
each repeat procedure.
The length of the repeat ablation hospital stay from the 
time of admission to the time of discharge as well as pre-
scription of antiarrhythmic drugs (Class 1 or III) at the time of 
discharge was assessed. Arrhythmia recurrence documenta-
tion was not collected during the FIRE AND ICE trial after the 
primary end point was met, but all-cause rehospitalizations 
and repeat ablations during follow-up after the first redo pro-
cedure were documented.
Statistical Analyses
Data analyses were conducted using the modified intent-
to-treat study populations (consistent with previous publi-
cations comparing subjects randomized to cryoballoon or 
RFC). The type of atrial arrhythmia recurrence before reab-
lation, the percent of patients with reconnected PVs, acute 
success, and the percent of patients prescribed antiarrhyth-
mic drugs postreablation were compared between the cryo-
balloon-Redo and RFC-Redo cohorts using exact methods. 
The hospital length of stay and time to repeat ablation were 
compared using the Wilcoxon rank-sum test. The number 
of reconnected PVs and the number of ablation lesions per-
formed during reablation were compared using a 2-sample 
t test. Freedom from rehospitalization and repeat reabla-
tion after the first redo procedure was assessed using the 
Kaplan-Meier method and the log-rank test.
Continuous variables are presented as mean±SD or 
median with interquartile range, as appropriate. Categorical 
variables are presented as absolute and relative frequen-
cies. There were no adjustments for multiple testing, and 
a P<0.05 was considered statistically significant. All analy-
ses were conducted using SAS software, version 9.4 (SAS 
Institute, Cary, NC) and R statistical package, version 3.2.2 
(https://www.r-project.org).
RESULTS
Patient Population
A total of 89 patients, 36 patients with cryoballoon 
(cryoballoon-Redo) and 53 patients with RFC (RFC-
Redo), from the FIRE AND ICE trial who underwent a 
repeat ablation were consented and enrolled (Table 1). 
The patients were 61±10 years old, 46% female, had a 
left ventricular ejection fraction of 62±7%, and an LA 
diameter of 41±7 mm at the time of enrollment into 
the original trial. There were no statistically significant 
differences in characteristics or comorbidities at the 
time of the index ablation between reablation cohorts 
(Table 2); however, there was a numerically higher per-
centage of women in the cryoballoon-Redo than in 
the RFC-Redo cohort (58% versus 38%, respectively; 
P=0.08). Most reablation patients, all originally treated 
Table 1. Patient Disposition
RFC 
Group
CB 
Group
Total 
Cohort
FIRE AND ICE trial
  Total FIRE AND ICE patients* 376 374 750
  Number of patients with reablations 66 44 110
FIRE AND ICE Redo study
  FIRE AND ICE Repeat patients† 53 36 89
  Repeat ablation with CB 0 13 13
  Repeat ablation with RFC 53 23 76
CB indicates cryoballoon; and RFC, radiofrequency current.
*Modified intention to treat cohort.
†Reconsented patients with a reablation during FIRE AND ICE.
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for paroxysmal AF, recurred with paroxysmal AF (61/89, 
69%); however, in 12/89 (13%) patients paroxysmal AF 
had progressed to persistent AF (Figure 1).
PV Reconnections at the Time of 
Reablation
The median time to first repeat ablation was not differ-
ent between cryoballoon-Redo and RFC-Redo cohorts 
(173 and 182 days, respectively; P=0.54). Data on the 
number of reconnected PVs identified during reablation 
were available in 98% (52/53) of RFC-Redo patients 
and 89% (32/36) of cryoballoon-Redo patients. 
Most patients in the RFC-Redo and cryoballoon-Redo 
cohorts had ≥1 reconnected PV at the time of repeat 
ablation (43/52 [83%] versus 25/32 [78%], respectively; 
P=0.78). Overall, the mean number of reconnected PVs 
per patient was significantly higher in the RFC-Redo 
cohort (2.1±1.4) than in the cryoballoon-Redo cohort 
(1.4±1.1; P=0.010; Figure 2A). The number of recon-
nected PVs per patient in both patient cohorts is depict-
ed in Figure 2B.
Specifically, in the cryoballoon-Redo cohort, there 
were significantly fewer reconnected left superior 
PVs (28% versus 60%; P=0.010) and a strong trend 
towards significantly fewer reconnected right superior 
PVs (29% versus 52%; P=0.07) than in the RFC-Redo 
cohort (Table 3). Left inferior PVs tended to reconnect 
less frequently after an index cryoballoon ablation than 
after an index RFC ablation (33% versus 50%, respec-
tively; P=0.17). There was no apparent difference in the 
incidence of right inferior PV reconnections between 
index treatment modalities (52% in RFC-Redo and 50% 
in cryoballoon-Redo; Table 3). Data on the number and 
specific location of lesion gaps according to quadrants 
or octants of the PV circumference were available for 
too few patients to perform meaningful analyses.
Reablation Procedural Characteristics
RFC catheter ablation was used in 85% (76/89) of 
all repeat ablation procedures regardless of the index 
PVI ablation modality. Specifically, 23/36 (64%) of 
cryoballoon-Redo patients and 53/53 (100%) of RFC-
Redo patients were retreated with RFC (Table 1). Of the 
Table 2. Baseline Patient Demographics and Comorbidities for Repeat 
Ablation Subjects
Characteristic*
RFC-Redo 
(n=53)
CB-Redo 
(n=36) P Values†
Age, y 60 ± 10 62 ± 11 0.48
Female sex 20 (38) 21 (58) 0.08
Diagnosed with PAF, y 4.5 (1.5–8.2) 3.7 (1.9–9.2) 0.86‡
Body mass index, kg/m2 27±4 28±5 0.60
HATCH score 1.2±1.1 1.5±1.2 0.23
CHA2DS2-VASc score 2 (1–2) 2 (1–3) 0.07‡
LV ejection fraction, % 62±7 62±7 0.88
LA diameter, mm 41.6±5.7 39.4±7.9 0.16
LA volume, mL 73±35 62±41 0.64
History of AFL 11 (21) 6 (17) 0.79
Prior DCCV 15 (28) 8 (22) 0.63
Prior stroke/TIA 2 (4) 2 (6) 1.00
AAD at discharge 35 (66) 22 (61) 0.66
Coronary artery disease 3 (6) 1 (3) 0.64
Prior MI 1 (2) 0 (0) 1.00
Prior CABG 2 (4) 0 (0) 0.51
Prior PCI 2 (4) 0 (0) 0.51
Aortic stenosis 0 (0) 0 (0) 1.00
Hypertension 32 (60) 22 (61) 1.00
Hyperlipidemia 13 (25) 12 (33) 0.47
Diabetes mellitus (type I or II) 5 (9) 4 (11) 1.00
Peripheral artery disease 0 (0) 0 (0) 1.00
Values are mean±SD, median (25th percentile, 75th percentile), or n/N 
(%). AAD indicates antiarrhythmic drug; AFL, atrial flutter; CABG, coronary 
artery bypass graft; CB, cryoballoon; DCCV, direct current cardioversion; 
HATCH, hypertension, age ≥75 years, transient ischemic attack or stroke, 
chronic obstructive pulmonary disease, heart failure; LA, left atrium; LV, left 
ventricular; MI, myocardial infarction; PAF, paroxysmal atrial fibrillation; PCI, 
percutaneous coronary intervention; RFC, radiofrequency current; and TIA, 
transient ischemic attack.
*Baseline patient characteristics collected at enrollment in FIRE AND ICE, 
before the index ablation.
†Fisher exact test for categorical variables, 2-sample t test for continuous 
variables.
‡Wilcoxon rank-sum test.
Figure 1. Recurrent arrhythmias before reablation. Paroxysmal atrial fibril-
lation (AF) was the most prevalent recurrent arrhythmia in both patient groups 
(68% in radiofrequency current [RFC]-Redo patients, 69% in cryoballoon [CB]-
Redo patients). Seven patients (13%) in the RFC-Redo group and 5 patients 
(14%) in the CB-Redo group progressed from paroxysmal to persistent AF. 
There was no difference in the type of atrial arrhythmia recurrence before 
reablation between cohorts (P=0.09). Numbers in stacked columns denote 
numbers of patients. AFL indicates atrial flutter; AT, atrial tachycardia; Atyp, 
atypical; PAF, paroxysmal atrial fibrillation; PersAF, persistent atrial fibrillation; 
and Typ, typical.
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patients treated with RFC at reablation, 6/23 (26%) 
and 16/53 (30%) of patients were treated with contact-
force sensing RFC catheters in the cryoballoon-Redo 
and RFC-Redo arms, respectively. The total number of 
ablations (PVs treated and non-PVI lesions) delivered 
during the repeat procedure in the RFC-Redo cohort 
(3.3±1.3) was significantly higher than the number of 
ablations delivered during reablation in the cryoballoon-
Redo cohort (2.5±1.5; P=0.015). While the mean num-
ber of PVs treated per patient in the RFC-Redo cohort 
had a tendency to be higher than in the cryoballoon-
Redo cohort (2.4±1.4 versus 1.8±1.4; P=0.07), there 
was no statistical difference in the per-patient num-
ber of non-PVI ablations delivered during reablation 
(P=0.32; Table  4). Acute reisolation was achieved in 
all PVs except for one right superior PV treated with 
RFC during reablation. A total of 42 (47%) reablation 
patients underwent non-PV ablation. Non-PVI lesions 
were applied exclusively with RFC and were success-
ful except for mitral valve isthmus lines (50% success) 
and cavotricuspid isthmus blocks (80% success; Table 
I in the Data Supplement). There were no differences 
in reablation procedural duration, LA dwell time, and 
fluoroscopy time between cohorts (Table 5).
Reablation Patient Follow-Up
The length of hospital stay following the first repeat 
ablation was not different between cryoballoon-Redo 
and RFC-Redo cohorts (median 2 [interquartile range, 
1–3] nights in both groups; P=0.65). There was also 
no difference in the percentage of patients prescribed 
antiarrhythmic drugs at discharge following the repeat 
ablation: 31/53 (58%) of RFC-Redo patients versus 
19/36 (53%) of cryoballoon-Redo patients (P=0.67). 
Patients in the cryoballoon-Redo and RFC-Redo cohorts 
were followed for 1.4±0.8 and 1.3±0.8 years after the 
first reablation, respectively. Kaplan-Meier estimates of 
1-year freedom from all-cause rehospitalization after the 
first reablation in the cryoballoon-Redo and RFC-Redo 
Figure 2. Pulmonary vein (PV) reconnections identified during repeat 
ablation.  
A, Mean number of reconnected PVs according to patient group. In the 
radiofrequency current (RFC)-Redo cohort a significantly higher mean number 
of reconnected PVs per patient than in the cryoballoon (CB)-Redo cohort was 
observed during repeat ablation (P=0.01). B, Percentage of patients with 0 to 
4 reconnected PVs per patient according to patient group.
Table 3. Reconnected PVs at Time of Reablation
RFC-Redo  
(n=52)
CB-Redo 
(n=32) P Values*
Total number of reconnected PVs
  Mean 2.1±1.4 1.4±1.1 0.010
  Median 2 1  
  LSPV 30/50 (60) 8/29 (28) 0.010
  LIPV 25/50 (50) 10/30 (33) 0.17
  LCPV 2/2 (100) 2/2 (100) 1.00
  RSPV 27/52 (52) 9/31 (29) 0.07
  RMPV NA NA  
  RIPV 27/52 (52) 16/32 (50) 1.00
Values are mean±SD or n/N (%). CB indicates cryoballoon; LCPV, left 
common pulmonary vein; LIPV, left inferior pulmonary vein; LSPV, left superior 
pulmonary vein; NA, not applicable; PV, pulmonary vein; RFC, radiofrequency 
current; RIPV, right inferior pulmonary vein; RMPV, right middle pulmonary 
vein; and RSPV, right superior pulmonary vein.
*Fisher exact test for categorical variables, 2-sample t test for continuous 
variables.
Table 4. PV and Non-PV Lesions Applied During Reablation
RFC-Redo 
(n=53)
CB-Redo 
(n=36) P Values*
Patients with >1 PV 
treated
47 (88.7) 28 (77.8) 0.24
Total ablation sets (PVs+non-PV)
  Mean 3.3±1.3 2.5±1.5 0.015
  Median 3 2  
PVs treated per patient
  Mean 2.4±1.4 1.8±1.4 0.07
  Median 2 2  
Patients with PVI-only 
ablations
24 (45.3) 23 (63.9) 0.13
Non-PV ablations per patient
  Mean 0.9±1.0 0.7±1.2 0.32
  Median 1 0  
Values are mean±SD or n (%). CB indiates cryoballoon; PV, pulmonary vein; 
PVI, pulmonary vein isolation; and RFC, radiofrequency current.
*Fisher exact test for categorical variables, 2-sample t test for continuous 
variables.
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cohorts were 81.8% (95% CI, 63.8%–91.4%) and 
84.3% (95% CI, 69.7%–92.3%), respectively (P=0.66). 
Kaplan-Meier estimates of 1-year freedom from anoth-
er reablation procedure were 97.0% (95% CI, 80.4%–
99.6%) for cryoballoon-Redo and 92.8% (95% CI, 
79.2%–97.6%) for RFC-Redo (P=0.98).
DISCUSSION
Main Findings
Main findings of this evaluation of PV lesion durability 
in patients who underwent repeat ablation after ran-
domization to an index PVI using either the cryoballoon 
or RFC are as follows:
• Regardless of the index ablation modality, the 
recurrent arrhythmia before reablation was par-
oxysmal AF in 69% of cases and persistent AF 
in 13%.
• At the time of reablation, the number of recon-
nected PVs per patient was significantly lower in 
patients initially treated with the cryoballoon than 
in patients initially treated with RFC.
• Cryoballoon-Redo patients, compared with RFC-
Redo patients, presented significantly less often 
with reconnected left superior PVs (28% versus 
60%) and exhibited a tendency for fewer recon-
nected left inferior PVs (33% versus 50%) and 
right superior PVs (29% versus 52%).
• Although RFC was predominantly used during 
the reablation procedure for both cohorts, sig-
nificantly fewer (PV and non-PV) ablation lesions 
were created per patient in the cryoballoon-Redo 
cohort. There was no difference between groups 
in the number of non-PV ablations applied per 
patient.
Reablation Patient Population
Overall, 15% of patients underwent a reablation dur-
ing the trial period, which is comparable to a random-
ized comparison of RFC and cryoballoon catheter abla-
tion that reported an overall 20% reablation rate at 12 
months.4,7 However, FIRE AND ICE showed that signifi-
cantly fewer patients randomized to cryoballoon abla-
tion underwent a repeat ablation (12% of patients with 
index cryoballoon) than patients randomized to RFC 
ablation (18% of patients with index RFC).4 Along with 
differences in rehospitalization, this may suggest that 
although the average time to first AF recurrence was 
not different, the patient-felt burden of AF recurrence 
necessitated less reintervention following cryoballoon 
than RFC ablation.9
Baseline characteristics collected at the time of 
enrollment in the FIRE AND ICE trial were not statistical-
ly different between cryoballoon-Redo and RFC-Redo 
patients, which suggests that observed differences in 
the present study were likely because of the index abla-
tion modality. While all patients presented with par-
oxysmal AF at the time of enrollment, ≈14% of these 
patients had progressed to persistent AF before the 
reablation procedure. The long history of AF (median of 
≈4 years before index ablation) in this reablation popu-
lation may have contributed to the observed disease 
progression.10,11
Index PVI Durability
This analysis demonstrated that at the time of repeat 
ablation, there were fewer reconnected PVs in patients 
whose index PVI was performed with the cryoballoon 
rather than RFC ablation, which is consistent with ret-
rospective analyses that have identified a significantly 
lower PV reconnection rate in cryoballoon cohorts at 
repeat ablation than RFC reablation cohorts (18.8% 
versus 34.6%; 20.4% versus 36.1%; and 36.8% ver-
sus 58.1%; respectively; all P<0.05).5–7 Specifically, sig-
nificantly fewer superior PV reconnections in patients 
treated with cryoballoon compared with RFC ablation 
have consistently been reported.5,6,8 These data may 
reflect differences in catheter stability in anatomically 
challenging locations. For example, significantly fewer 
reconnected left superior PVs were observed in the 
cryoballoon-Redo cohort. Stable, point-by-point RFC 
ablation, mandatory for creation of a contiguous and 
transmural ablation line, may not be readily achieved 
along the myocardial ridge separating the left-sided 
PVs from the LA appendage (which may be only a 
few millimeters in width particularly at the left supe-
rior PV12). In contrast, the cryoballoon only needs to 
be placed firmly in either PV ostium to achieve PVI in a 
single freeze; therefore, the myocardial ridge does not 
affect the ability of the cryoballoon to create durable 
lesions in this area. Similarly, the cryoballoon can ablate 
the right superior PV with relative ease compared with 
the difficulty of achieving RFC catheter stability at 
the posterosuperior aspect of the LA, particularly in 
situations of deep respiratory excursion.8 There was 
no observed difference in right inferior PV reconnec-
tion rates between cryoballoon-Redo and RFC-Redo 
Table 5. Repeat Ablation Procedure Times
RFC-Redo (n=53) CB-Redo (n=36) P Values*
Total procedure 
time, min
115 (87–140); (n=23) 109 (82–120); (n=18) 0.38*
LA dwell time, 
min
84 (55–95); (n=11) 77 (67–110); (n=7) 1.00*
Fluoroscopy 
time, min
16.6±10; (n=45) 17.0±9.6; (n=33) 0.86†
Values are median (25th percentile–75th percentile) or mean±SD. CB 
indicates cryoballoon; LA, left atrium; and RFC, radiofrequency current.
*Wilcoxon rank-sum test.
†Two-sample t test.
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cohorts. This may be because the inferior most aspect 
of the right inferior PV can be challenging to access 
(particularly if the site of transseptal puncture is too 
high in relation to the right inferior PV or if the PV 
is located too low in relation to the site of a proper 
transseptal puncture) with either ablation modality.8 
Measurement of contact force can provide a surrogate 
measure of catheter stability, but even an increase in 
power may not necessarily overcome inadequate lesion 
formation from RFC catheter instability leading to PV 
reconnection over time.13 A randomized controlled trial 
is required to show whether the ablation index will lead 
to improved outcomes of PVI via point-by-point RFC 
ablation, as suggested in a recent observational study.14
Invasive and noninvasive investigations of PVI dura-
bility in all study patients have corroborated results 
from studies in reablation cohorts. The EFFICAS II trial 
identified that 63% of all 24 enrolled patients were 
free from PV lesion gaps during a remapping proce-
dure 3 months after the index RFC PVI, while durable 
PVI was observed in 79% of the 21 patients evaluated 
3 months after second-generation cryoballoon PVI in 
the SUPIR trial.13,15 Gadolinium enhanced cardiac mag-
netic resonance imaging has been leveraged to nonin-
vasively assess chronic lesion durability and identified 
that cryoballoon ablation resulted in fewer gaps in PV 
lesions 1 to 3 months following the index PVI compared 
with RFC ablation.16 Together, these data suggest that 
cryoballoon ablation results in more durable PVI than 
RFC ablation regardless of whether patients ultimately 
required a repeat ablation.
Repeat Ablation Procedural 
Characteristics
This study demonstrated that fewer lesions at the time 
of repeat ablation were required to reisolate the PVs in 
patients initially treated with cryoballoon versus RFC. 
This is likely a consequence of fewer reconnected PVs in 
the cryoballoon-Redo cohort compared with the RFC-
Redo cohort. However, a total of 47% of reablation 
patients were also treated with non-PV lesions during 
the repeat procedures in this study. The number of non-
PV lesions applied during the repeat procedure did not 
differ between cohorts, which may suggest there was 
a similar contribution of non-PV triggers to AF recur-
rence between cryoballoon-Redo patients and RFC-
Redo patients.
Although it was recommended to treat patients 
with the same ablation modality used in the index 
procedure, RFC was used in 85% of all repeat abla-
tions in this trial. Therefore, procedural characteris-
tics and freedom from rehospitalization and reabla-
tion were not different between cryoballoon-Redo 
and RFC-Redo cohorts. The rationale for the catheter 
selected during the reablation was not documented, 
but the tendency to use RFC during the repeat proce-
dure may reflect a desire for flexibility to target tissue 
adjunctive to the PVs in the event the operator deems 
it necessary. However, studies that have investigated 
cryoballoon usage during a repeat ablation following 
an index intervention with either cryoballoon or RFC 
ablation report freedom from AF recurrence at 1 year 
in 60% to 70% and 83% of patients, respectively.17–19 
A randomized comparison of RFC versus cryoballoon 
ablation during repeat ablation did not identify a dif-
ference in freedom from AF at 1-year postreablation.20 
Together, these data suggest that the cryoballoon may 
be an underutilized tool for reablation procedures and 
warrant future studies to evaluate reablation success 
with the cryoballoon.
Limitations
Although patients in this study were prospectively 
randomized to either cryoballoon or RFC index PVI, 
the treatment that patients received during the repeat 
procedure was no longer randomized. Physicians were 
encouraged to use the same energy source in a repeat 
ablation as was used during the index procedure, but 
this guidance was not well adhered to outside the 
90-day blanking period. This retrospective collection 
of data did not result in complete records to fulfill 
all study objectives from all patients, and the spe-
cific location(s) that initiated AF recurrence were not 
documented. Institutional variation in the information 
recorded during the repeat ablation and inconsistent 
definitions of study measurements prevented inclu-
sion and analysis of all data. Some intended study 
objectives (eg, lesion gap information) were unable 
to be addressed because of insufficient information 
to perform meaningful statistics. Further, the original 
FIRE AND ICE protocol was not designed to document 
AF recurrence after the primary end point was met; 
therefore, the risk of AF recurrence after reablation 
cannot be reported in this analysis.
Conclusions
The FIRE AND ICE trial showed that patients treated 
with cryoballoon ablation required a repeat ablation 
less often than patients treated with RFC ablation. The 
present analysis demonstrated that of those patients 
who underwent reablation, cryoballoon-Redo patients 
had fewer reconnected PVs, particularly left superior 
PVs, with a strong trend observed in right superior PVs. 
These data may indicate that catheter stability man-
datory to achieve durable PVI is more aptly achieved 
with the cryoballoon catheter than with RFC catheters. 
Accordingly, patients initially treated with cryoballoon 
PVI required fewer reablation lesions than patients ini-
tially treated with RFC PVI.
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